President Shavkat Mirziyoyev visited the Tashkent Pharma Park cluster.

The complex was established in accordance with the decree of the head of state dated January 28, 2020, and the first stone was laid on April 17 of the same year.

In the first phase, a technopark is being constructed on an area of about 20 hectares, which includes an administrative center, a research and development (R&D) center, a laboratory for the safety control of pharmaceutical products, a clinical research center, a Pharmaceutical Technical University, and an animal facility.

As of today, the construction of the administrative center has been completed. The 11-story building houses the Agency for the Development of the Pharmaceutical Industry, a conference hall, a coworking center, a business incubator, a museum of industry history, and a library.

The President was briefed on the agency and the progress of the construction of the other buildings.

It was noted that the main objectives of the cluster are to develop the country's pharmaceutical industry through the implementation of advanced technologies, integration into the international innovation system, production of high-quality medicines, medical devices, and equipment, as well as training qualified specialists. To achieve these ambitious goals, a 190-hectare land plot has been allocated in the Zangiata district of Tashkent region.

In the industrial zone, 21 projects have been launched with a total investment of $818 million. The first of these is the Grand Pharm Logistics Hub distribution center, which cost $40 million and has created 300 jobs. The enterprises are being established in collaboration with companies from Turkey, India, China, Malaysia, the United Arab Emirates, and Russia.

The President spoke with the project initiators. It was emphasized that attracting and supporting investments will continue systematically.

In the future, the industrial zone plans to implement 20 projects worth $620 million.

Overall, the cluster will produce high-quality medicines and medical devices, localized products, thereby creating 8,000 jobs. The Good Practices Center (GxP) will ensure quality and compliance of products at all stages from production to delivery to consumers.

The head of state was also presented with information about the Pharmaceutical Technical University, which will be part of the cluster.

The university will feature a pharmacopoeial center, a library, a sports complex, and housing for teachers and foreign specialists. It will prepare highly qualified specialists in the fields of industrial pharmacy, biomedicine, biochemistry, biotechnology, biopharmaceutics, and pharmaceutical chemistry.

To achieve this, education will be organized based on international programs, and laboratories in microbiology, biotechnology, cell biology, pharmacology, and analytical chemistry will be established.